170 related articles for article (PubMed ID: 22650123)
1. [Overactive bladder after transurethral resection of prostate treated with electroacupuncture therapy and tolterodine].
Shen YZ; Lin X; Lin Q
Zhongguo Zhen Jiu; 2012 May; 32(5):404-8. PubMed ID: 22650123
[TBL] [Abstract][Full Text] [Related]
2. [Parkinson's disease combined with overactive bladder syndrome treated with acupuncture and medication].
Chen YL; Feng WJ; Zhang XL
Zhongguo Zhen Jiu; 2012 Mar; 32(3):215-8. PubMed ID: 22471132
[TBL] [Abstract][Full Text] [Related]
3. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication.
Klutke CG; Burgio KL; Wyman JF; Guan Z; Sun F; Berriman S; Bavendam T
J Urol; 2009 Jun; 181(6):2599-607. PubMed ID: 19375110
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
Peters KM; Macdiarmid SA; Wooldridge LS; Leong FC; Shobeiri SA; Rovner ES; Siegel SW; Tate SB; Jarnagin BK; Rosenblatt PL; Feagins BA
J Urol; 2009 Sep; 182(3):1055-61. PubMed ID: 19616802
[TBL] [Abstract][Full Text] [Related]
7. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
8. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
[TBL] [Abstract][Full Text] [Related]
9. [Tolterodine for bladder spasm caused by the indwelling catheter after prostate operation].
Chen Q; Xue W; Wang Y; Lu J; Huang Y
Zhonghua Nan Ke Xue; 2004 May; 10(5):374-5. PubMed ID: 15190834
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
11. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
12. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
13. [Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity].
Gan W; Zhang SF; Jia HT; Xie S; Luo MH; Li YF
Zhonghua Nan Ke Xue; 2011 Apr; 17(4):348-50. PubMed ID: 21548214
[TBL] [Abstract][Full Text] [Related]
14. [Cardura monotherapy versus combination therapy of cardura and tolterodine L-tartrate tablets for II° ? benign prostatic hyperplasia with overactive bladder].
Wang YY; Shi GW; He JY; Zhang YB
Zhonghua Nan Ke Xue; 2013 Dec; 19(12):1099-102. PubMed ID: 24432622
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
16. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
Malone-Lee JG; Al-Buheissi S
BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
[TBL] [Abstract][Full Text] [Related]
17. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
Malone-Lee J; Shaffu B; Anand C; Powell C
J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams.
Chung DE; Te AE; Staskin DR; Kaplan SA
Urology; 2010 May; 75(5):1144-8. PubMed ID: 20206978
[TBL] [Abstract][Full Text] [Related]
19. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.
Hsiao SM; Chang TC; Wu WY; Chen CH; Yu HJ; Lin HH
J Obstet Gynaecol Res; 2011 Aug; 37(8):1084-91. PubMed ID: 21501328
[TBL] [Abstract][Full Text] [Related]
20. Tolterodine for treatment of overactive bladder.
Kanofsky JA; Nitti VW
Urol Clin North Am; 2006 Nov; 33(4):447-53, viii. PubMed ID: 17011380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
